Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy

Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 606906
Main Authors Ma, Yifan, Dong, Shiyan, Li, Xuefeng, Kim, Betty Y S, Yang, Zhaogang, Jiang, Wen
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 08.02.2021
Subjects
cancer therapy
drug delivery
exosome
extracellular vesicle
Oncology
therapeutic nanoplatform
cancer therapy
therapeutic nanoplatform
drug delivery
exosome
extracellular vesicle
Online AccessGet full text

Cover

More Information
Summary:Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs' therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Luis Alexandre Muehlmann, University of Brasilia, Brazil
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Reviewed by: Gaoxing Su, Nantong University, China; Luca Tamagnone, Institute for Cancer Research and Treatment (IRCC), Italy
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.606906